CD19 and acute lymphoblastic leukemia: The most important clinical trial testing a CD28-costimulated anti-CD19 CAR T cell in ALL is ZUMA-3, whose Phase II has driven the FDA and EMA approval of KTE-X19 (brexucabtageneautoleucel, Tecartus©) for commercial use in adults with R/R B-ALL.